gantenerumab

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Short description|Monoclonal antibody protein}}{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458275293

| image = Gantenerumab_Aβ(1–11)_5CSZ.png

| caption = Fab fragment of gantenerumab (blue) encircling and binding an Aβ(1–11) fibril (bright green). {{PDB|5CSZ}}.

| type = mab

| mab_type = mab

| source = u

| target = Beta-amyloid (Aβ40/42)

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status = Investigational

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|CAS}}

| CAS_number = 1043556-46-2

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 4DF060P933

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D09680

| C=6496 | H=10072 | N=1740 | O=2024 | S=42

}}

Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease being developed by Hoffmann-La Roche pharmaceuticals.{{cite web | url = http://www.ama-assn.org/ama1/pub/upload/mm/365/gantenerumab.pdf | title = Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab | publisher = American Medical Association }}{{cite web | url = http://whqlibdoc.who.int/druginfo/INN_2008_list59.pdf | title = International Nonproprietary Names for Pharmaceutical Substances (INN) | archive-url = https://web.archive.org/web/20120211192453/http://whqlibdoc.who.int/druginfo/INN_2008_list59.pdf | archive-date=2012-02-11 | publisher = World Health Organization }}

Gantenerumab binds to and clears aggregated beta amyloid fibers.{{cite journal | vauthors = Panza F, Seripa D, Lozupone M, Solfrizzi V, Imbimbo BP, Barulli MR, Tortelli R, Capozzo R, Bisceglia P, Dimitri A, Stallone R, Dibello V, Quaranta N, Daniele A, Bellomo A, Greco A, Logroscino G | title = The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset | journal = Expert Opinion on Biological Therapy | volume = 18 | issue = 1 | pages = 25–35 | date = January 2018 | pmid = 29037101 | doi = 10.1080/14712598.2018.1389885 | s2cid = 4795458 }}

A phase III clinical trial of gantenerumab was stopped early because of a lack of efficacy.{{cite journal | vauthors = Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P | title = A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease | journal = Alzheimer's Research & Therapy | volume = 9 | issue = 1 | pages = 95 | date = December 2017 | pmid = 29221491 | pmc = 5723032 | doi = 10.1186/s13195-017-0318-y | doi-access = free }} Gantenerumab was also evaluated in younger patients at high risk of developing Alzheimer's disease{{ClinicalTrialsGov|NCT01760005|Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)}} but after five years of treatment, the drug did little to slow cognitive decline in patients.{{cite web | vauthors = Kolata G | date = 10 February 2020 | title = An Alzheimer's Treatment Fails: 'We Don't Have Anything Now' | work = The New York Times | url = https://www.nytimes.com/2020/02/10/health/alzheimers-amyloid-drug.html }}

A study published in 2025 suggests that Gantenerumab appears to reduce the risk of Alzheimer's-related dementia in people with rare genetic mutations mutations that cause the overproduction of amyloid in the brain. These people are normally destined to develop the disease in their 30s, 40s or 50s.{{cite journal | vauthors = Bateman RJ, Li Y, McDade EM, Llibre-Guerra JJ, Clifford DB, Atri A, Mills SL, Santacruz AM, Wang G, Supnet C, Benzinger TL, Gordon BA, Ibanez L, Klein G, Baudler M, Doody RS, Delmar P, Kerchner GA, Bittner T, Wojtowicz J, Bonni A, Fontoura P, Hofmann C, Kulic L, Hassenstab J, Aschenbrenner AJ, Perrin RJ, Cruchaga C, Renton AE, Xiong C, Goate AA, Morris JC, Holtzman DM, Snider BJ, Mummery C, Brooks WS, Wallon D, Berman SB, Roberson E, Masters CL, Galasko DR, Jayadev S, Sanchez-Valle R, Pariente J, Kinsella J, van Dyck CH, Gauthier S, Hsiung GR, Masellis M, Dubois B, Honig LS, Jack CR, Daniels A, Aguillón D, Allegri R, Chhatwal J, Day G, Fox NC, Huey E, Ikeuchi T, Jucker M, Lee JH, Levey AI, Levin J, Lopera F, Roh J, Rosa-Neto P, Schofield PR | title = Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial | language = English | journal = The Lancet. Neurology | volume = 24 | issue = 4 | pages = 316–330 | date = April 2025 | pmid = 40120616 | doi = 10.1016/S1474-4422(25)00024-9 }}